Product Description
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Brazil | Chile | Dominican Republic | Egypt | France | Ireland | Italy | Korea | Lebanon | Morocco | New Zealand | Peru | Portugal | Russia | Spain | Taiwan | Tunisia | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pierre Fabre Laboratories
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Rhinitis, Allergic, Seasonal|Chikungunya Fever
Phase 2: Overactive Bladder|Asthma|Rhinitis, Allergic, Seasonal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2013-002517-35 | P2 |
Completed |
Asthma |
2014-04-22 |
|
2008-001860-36 | P3 |
Completed |
Rhinitis, Allergic, Seasonal |
2013-05-29 |
|
2010-024271-10 | P2 |
Terminated |
Overactive Bladder |
2011-09-14 |
|
2006-006165-17 | P3 |
Active, not recruiting |
Chikungunya Fever |
2007-12-20 |